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Abstract
CD36 facilitates oxidized low density lipoprotein uptake and is implicated in development of atherosclerotic lesions. CD36
also binds unmodified high and very low density lipoproteins (HDL, VLDL) but its role in the metabolism of these particles is
unclear. Several polymorphisms in the CD36 gene were recently shown to associate with serum HDL cholesterol. To gain
insight into potential mechanisms for these associations we examined HDL metabolism in CD36 null (CD36
2/2) mice.
Feeding CD36
2/2 mice a high cholesterol diet significantly increased serum HDL, cholesterol and phospholipids, as
compared to wild type mice. HDL apolipoproteins apoA-I and apoA-IV were increased and shifted to higher density HDL
fractions suggesting altered particle maturation. Clearance of dual-labeled HDL was unchanged in CD36
2/2 mice and
cholesterol uptake from HDL or LDL by isolated CD36
2/2 hepatocytes was unaltered. However, CD36
2/2 hepatocytes had
higher cholesterol and phospholipid efflux rates. In addition, expression and secretion of apoA-I and apoA-IV were increased
reflecting enhanced PXR. Similar to hepatocytes, cholesterol and phospholipid efflux were enhanced in CD36
2/2
macrophages without changes in protein levels of ABCA1, ABCG1 or SR-B1. However, biotinylation assays showed increased
surface ABCA1 localization in CD36
2/2 cells. In conclusion, CD36 influences reverse cholesterol transport and hepatic ApoA-I
production. Both pathways are enhanced in CD36 deficiency, increasing HDL concentrations, which suggests the potential
benefit of CD36 inhibition.
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Introduction
Cluster of Differentiation 36 (CD36) is an 88 kD transmem-
brane glycoprotein and type B scavenger receptor with a range of
lipid ligands that includes long chain fatty acids (FA)[1] and native
or modified lipoproteins[2]. As a result, CD36 is implicated in
various cellular activities linked to a number of pathologies
including atherosclerosis[3]. Cholesterol uptake by macrophages
from oxidized low density lipoproteins (ox-LDL) or LDL promotes
formation of lipid-laden ‘‘foam’’ cells, a critical step in atheroscle-
rotic lesion formation. CD36 facilitates ox-LDL uptake by binding
the modified lipids and internalizing the particles [4]. CD36 was
also shown to delay degradation of native LDL in vivo[5]. These
two functions would be predicted to have a pro-atherosclerotic
effect.
High density lipoproteins (HDL) have an antiatherogenic effect
reflecting their function in reverse cholesterol transport to the liver
and their anti-oxidant properties[6]. Like SR-B1, a family member
and HDL receptor[7], CD36 binds these particles with high
affinity[8,9]. However, its efficiency in mediating selective
cholesteryl ester (CE) uptake is low compared to SR-B1[9,10],
which led to the concept that it has a minor if any role in HDL
metabolism. In CD36 null (CD36
2/2) mice fed a chow diet,
plasma cholesterol and HDL are modestly elevated (about
30%)[11], but the significance of this observation is unclear.
HDL level is influenced by that of very low density lipoproteins
(VLDL) and an inverse relationship is often observed between
serum levels of both lipoproteins[12]. High VLDL as a result of
increased hepatic secretion[12] or diminished clearance due to
lipoprotein lipase deficiency[13] usually associate with low HDL.
A major phenotypic characteristic of CD36
2/2 mice is a defect in
tissue FA uptake that feedbacks to inhibit VLDL clearance[14,15].
However, the expected inverse relationship between VLDL and
HDL does not hold in the CD36
2/2 mouse where both
lipoproteins were reported to be increased[11]. Recent evidence
suggested the possibility that CD36 may play a direct role in
HDL metabolism. A region of chromosome 7 (7q11.2–7q21.11)
encompassing the CD36 gene was linked to components of the
metabolic syndrome including HDL in genome-wide linkage
studies[16]. Our study in a large population sample identified
strong associations between single nucleotide polymorphisms
(SNPs) in the CD36 gene and serum HDL cholesterol[17]. Of
thirty-six CD36 tag SNPs that were examined, nine associated
with increased serum HDL-C and seven with reduced HDL-C.
These associations remained significant after adjusting for
triglyceride (TG) levels consistent with a direct effect. These
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may be underappreciated.
In this report we describe the impact of CD36 deficiency in
mice on HDL metabolism and examine the mechanisms involved.
Our results implicate CD36 in reverse cholesterol transport and in
hepatic secretion of HDL apolipoproteins, two processes that
influence HDL levels.
Materials and Methods
Animals and diets
CD36
2/2 mice[11] on the C57BL/6J genetic background were
housed in a barrier facility with free access to food and water. For
the high cholesterol feeding studies, 8 week-old mice were
maintained on a high fat, high cholesterol (HFHC) diet (Teklad
Harlan, TD.02028, 42% calories from fat, 1.25% cholesterol) for 4
weeks. For studies with isolated hepatocytes and macrophages and
in vivo HDL clearance 12 week-old mice fed CHOW were used. All
experimental protocols were performed in compliance with the
standards established by the US Animal Welfare Acts, and were
approved by the Animal Study Committee of Washington
University School of Medicine.
Plasma lipid measurements
Plasma lipids were measured using 12 hours fasted mice. Blood
samples, 50 ml, were collected from the mouse tail vein in heparin
coated capillaries, and plasma was obtained by centrifugation at
12,000 g for 5 minutes at 4uC. Plasma triglyceride (TG), total
cholesterol (CHOL), HDL-cholesterol, phospholipids (PL), and
free fatty acids (FA) were measured using enzymatic kits (Wako
Chemicals, Richmond, VA).
Lipoprotein fractionation was conducted by fast protein liquid
chromatography (FPLC) using a Superose 6 column HR13/50
and pooled plasma from 4 mice (5–6 hr after food removal in the
morning). A total of 45–0.5 ml samples were collected from each
fractionation. Cholesterol concentration was measured as de-
scribed above, and lipoprotein apoA-I and apoA-IV distribution
was determined by Western blot analysis as described below.
Lipoprotein isolation and labeling
Plasma from human donors was subjected to serial gradient
ultracentrifugation as described[18]. LDL was isolated from the
density range 1.019 to 1.063 g/ml, HDL2 from 1.063–1.125 g/ml
and HDL3 from 1.125–1.210 g/ml. Isolated lipoproteins were
dialyzed against 4 L of 0.8% saline-EDTA overnight at 4uC under
nitrogen gas. Protein concentration was determined using the
BCA assay (Bio-Rad, Hercules, CA).
Acetylated-LDL (ac-LDL) were prepared and labeled as
described[19]. Briefly, LDL isolated from human plasma (0.5–
1.0 mg protein/ml) was diluted 1:1 with saturated sodium acetate
while continuously stirred on ice. Acetic anhydride was added with
stirring in aliquots (2 ml) and up to 1.5 times the protein mass
(1.5 ml/mg). The mixture was stirred for 30 more min then
dialyzed (24–36 h, 4uC) against 2 liters of buffer (0.15 M NaCl,
0.3 mM EDTA, pH 7.4) with 6 changes (total 12 L). Protein
content was determined after dialysis. LDL or ac-LDL (1 ml,
0.5 mg protein) were labelled [20] either with
3H-cholesterol-
oleate (50 mCi, Perkin Elmer Life Sciences) or
14C-cholesterol
(50 mCi, American Radiolabeled Chemicals, St. Louis, MO).
For HDL clearance assay, human HDL3 were dual labeled with
125I-dilactitol tyramine and
3H-cholesteryl oleolyl ether [9,21].
The
125I/
3H-hHDL3 was dialyzed against buffer (0.15 M NaCl,
0.3 mM EDTA) to remove free label. Specific activity was
20.860.1 (
125I) and 6.460.3 (
3H) dpm/ng protein.
In vivo HDL clearance
Anesthetized mice (5 females and 10 males per genotype) were
injected 0.2-ml of labeled hHDL3 (,180 mg hHDL3 protein,
1.7 mCi
125I and 0.5 mCi
3H) via the external jugular vein [22,23].
Venous blood was collected from the retro-orbital plexus in
heparin-coated capillaries (,50 ml) at 1, 5, 10, 20, 30 40, 60, 90,
120, 180, and 240 minutes later. Radioactivity (
3H and
125I) was
counted in plasma and normalized to HDL concentration. Data
are expressed as percent of levels at 1 min after injection.
In vitro HDL and LDL uptake by primary hepatocytes
Mouse hepatocytes were isolated [24] and maintained in
DMEM with 10% FBS. For HDL assays, dual-labeled HDL3
were added to the media (0.1, 0.2, and 0.3 mg/ml HDL3) for 3 hr.
The medium was then removed and the cells washed with PBS
before lysis in 0.2N NaOH for radioactivity counts, later adjusted
for protein content. For LDL assays, hepatocytes were incubated
with
3H-cholesteryl oleolyl labeled hLDL (0.1 mg/ml) for 5 hr
before processing as for HDL uptake.
ApoA-I and apoA-IV synthesis and secretion by primary
hepatocytes
Synthesis and secretion of apoA-I and apoA-IV by primary
hepatocytes were determined using
35S labeled methionine and
cysteine[25]. Freshly isolated hepatocytes were incubated in
methionine and cysteine-free DMEM (Sigma Aldrich, St. Louis,
MO) for 30 minute then switched to the same medium but with
5 mCi/ml
35S labeled Met and Cys (Easytag Protein Labeling mix,
Perkin Elmer, Waltham, MA) for 3 hr. Medium and cells were
harvested, and immunoprecipitated again apoA-I, apoA-IV, and
albumin antibodies. Proteins were separated by SDS-PAGE, fixed,
dried, and exposed against X-ray film. Albumin abundance was
used as an internal standard.
Cholesterol and phospholipid efflux assays in primary
hepatocytes and macrophages
Mice were intraperitoneally injected with 2 ml of 4.5%
thioglycollate 4 days before harvesting peritoneal macrophages
by lavage[26]. The macrophages were incubated overnight in 12-
well plates (0.5610
6 cells/well) in RPMI-1640 supplemented with
10% FBS and antibiotics.
Cholesterol and phospholipid efflux assays were as described
[20,27]. For cholesterol efflux, the cells were loaded with
cholesterol for 18 hr in DMEM (hepatocyte) or RPMI-1640
(macrophage) with 0.2% FA-free BSA, labeled LDL or ac-LDL
(1 mCi/well) and ACAT inhibitor (10 nM oleic acid-2,6-diisopro-
pylanilide, Cayman Chemical Co., Ann Arbor, MI). The next day,
the cells were washed twice with pre-warmed PBS and incubated
in fresh DMEM- or RPMI-0.2% BSA for 15 min before switching
to medium containing isolated hHDL2 or purified human apoA-I
(A0722, Sigma-Aldrich, St. Louis, MO) at the indicated
concentrations for a 12 hr efflux assay. Media were collected
and cleared from cell debris by centrifugation. Cells were washed
and scrapped in cold PBS with proteinase inhibitor (Sigma-
Aldrich, St. Louis, MO). For phospholipid efflux assays, cellular
phospholipids were labeled by incubating the cells with 0.5 mCi
[
3H]-choline (American Radiolabeled Chemicals, St. Louis, MO)
in DMEM or RPMI-10% FBS for 24 hr. After washing the cells
were incubated in serum-free medium with hHDL2 for 12 hr.
Media and cells were then extracted for lipids (chloroform/
methanol, 1:1, v/v). Lipid radioactivity was counted and adjusted
for cellular protein content.
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For biotin labeling of surface proteins[28] cells were incubated
in PBS (with 0.1 mM Ca
2+, 0.5 mM Mg
2+) with 500 mg/ml sulfo-
succinimido-biotin (Pierce-Thermo Scientific, Waltham, MA) for
30 min at 4uC. The washed cells were lysed (50 mM Tris, 1 mM
EDTA, 1%Triton, 2%SDS, 1X proteinase inhibitor, pH=7.4)
and about 10% of lysates was saved for protein assays. The rest
was used for immunoprecipitation of biotin-labeled proteins using
streptavidin-magnetic beads (2 hrs, 4uC). Biotin-labeled proteins
were separated by SDS-PAGE alongside total cell proteins.
Antibodies for Cadherin 1(CDH1, Abcam, Cambridge, MA) was
used as a cell membrane marker.
RT-PCR
Total liver RNA was isolated using Trizol (Invitrogen, Carlsbad,
CA) and further purified by RNeasy columns (Qiagen Sciences,
Valencia, CA). cDNA was synthesized using high capacity cDNA
reverse transcription kit (Applied biosystems, Foster City, CA) and
changes in transcript abundance were measured using SYBR-
green PCR Master kit on a ABI-7500 real-time PCR system. For
each genotype, mRNA from 8 mice was randomly combined
to form 2 pools of equal concentration. Each primer pair was
repeated 3 times on a 96-wells plate (6 measurements per
genotype) and duplicate plates were used. The 36B4 gene was
used as a normalization standard. The RT-PCR primer sequences
and relevant references were listed in Table S1.
Western Blots
Proteins separated by SDS-PAGE were transferred to a PVDF
membrane (Millipore, St. Charles, MO) and probed with
antibodies. Polyclonal antibodies against mouse apoB, apoA-I,
apoA-IV, and apoE were generated and used as reported[24].
Rabbit polyclonal antibody against mouse SR-B1 (Novus
Biologicals, Litteton, CO), mouse monoclonal antibodies against
ABCA1, ABCG1, CDH1(Abcam, Cambridge, MA), PPARc and
b-Actin (Santa Cruz Biotech, CA) were used as recommended by
the manufacturers. Immune signals were detected and quantified
using LI-COR Odyssey Imaging (Lincoln, NE) with near-infrared
dye labeled secondary antibodies except for
35S labeling of hepatic
apolipoprotein synthesis and secretion where X-ray film was used.
Statistical Analysis
Statistical analyses used SAS (9.02 Cary, NC). Differences were
considered significant if the p-value was less than 0.05.
Results
HDL levels and distribution in CD36
2/2 and WT mice fed
a high cholesterol diet
The initial report on CD36 deficient mice fed a chow diet with
4% fat described a modest increase (30%) of plasma cholesterol
and HDL as compared to WT mice[11] but increased HDL were
not noted in other studies[5,29]. As shown in Table 1, we
confirmed observations[11] of significantly higher plasma choles-
terol in CD36
2/2 as compared to WT mice maintained on chow
and the difference was observed in both males and females.
Phospholipid (PL) levels were also increased in female but not in
male CD36
2/2 mice. To further validate the differences in HDL
levels between the genotypes, the mice were challenged with a
high fat, high cholesterol (HFHC) diet for 4 weeks. The HFHC
diet significantly increased blood cholesterol and PL (Table 1) in
all mice. However, levels of both lipids were significantly higher
(1.5–2 fold) in CD36
2/2, as compared to WT mice, regardless of
sex. The increased serum cholesterol was primarily localized to
HDL subfractions as shown in Figure 1(A and B). Consistent with
the higher HDL concentrations, plasma levels of HDL constituent
apolipoproteins, apoA-I and apoA-IV, were also higher in
CD36
2/2mice (Figure 1C). On the other hand, levels of apoB48
and apoE (components of chylomicrons and VLDL) were similar.
Figure 1C also shows that the apolipoprotein profile was not
altered by the diet except for a HFHC-induced increase in apoE
levels. These data showed that CD36
2/2 mice exhibit higher
levels of plasma cholesterol than WT mice and this difference is
exaggerated upon feeding a cholesterol rich diet. The higher HDL
levels were present in male and female mice and were not altered
by the nutritional state of the mice; HDL levels, in fed versus 6 and
14 hr fasted mice were reproducibly higher in CD36
2/2 as
compared to WT mice (data not shown).
We next examined whether there were changes in apolipopro-
tein content of HDL subfractions collected from FPLC. As
shown in Figure 1D and E, apoA-I and apoA-IV distribution in
CD36
2/2 samples shifted to higher density fractions (more
apparent in female mice) suggesting presence of more lipid poor
HDL particles.
In vivo HDL clearance
A major regulator of plasma HDL levels is HDL clearance by
hepatocyte-mediated selective CE uptake[30]. Adenoviral overex-
pression of CD36 in the liver was previously found not to alter
plasma HDL[10]. We examined whether CD36 deletion, which
alters plasma HDL, impacts HDL clearance by reducing hepatic
CE uptake[9]. CD36 deficiency could also impact the process
indirectly through altered activation of peroxisome proliferator-
activated receptors (PPARs)[31] which modulate several aspects of
lipoprotein metabolism[32]. We quantified in vivo HDL catabolism
using
125I (apolipoprotein) and
3H-cholesteryl oleolyl ether dual-
labeled human HDL3. Each mouse was injected with 200 mlo f
labeled lipoprotein and plasma radioactivity was measured
over 2 hrs. Counts were adjusted for the higher HDL levels in
CD36
2/2 mice. As shown in Figure 2, there was no difference in
HDL-CE clearance rate between genotypes (Fig. 2A) and
clearance of
125I-HDL apolipoprotein was also similar (Fig. 2B).
Table 1. Serum phospholipids and cholesterol in WT and
CD36null mice fed chow or high fat high cholesterol diets for
4 weeks.
Gender WT CD36
2/2 P value
CHOW
Chol (mg/dL) F 83.067.4 132.3618.2 0.001
M 83.267.0 111.5615.7 0.003
PL (mg/dL) F 62.667.5 135.367.7 ,0.001
M 95.367.8 73.3632.8 0.196
HFHC
Chol (mg/dL) F 128.4631.1 194.7623.3 ,0.001
M 138.6651.2 236.8656.8 ,0.001
PL (mg/dL) F 87.0618.2 185.5622 ,0.001
M 126.9632.4 186.0642.9 0.035
1. Parameters are from 12-week old mice after an overnight fast, n=8
per genotype.
2. P value is for differences between WT and CD36
2/2 mice.
3. Chol, cholesterol; PL, phospholipids.
doi:10.1371/journal.pone.0009906.t001
CD36 Influences HDL Metabolism
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9906This suggested that HDL clearance does not contribute to
elevating plasma HDL in CD36
2/2 mice.
HDL and LDL uptake by isolated hepatocytes
To further validate the interpretation that hepatic HDL
clearance is not altered in CD36
2/2 mice, we compared directly
in vitro selective CE uptake by primary hepatocytes isolated from
WT and CD36
2/2 mice. The cells were incubated with different
concentrations (0.1, 0.2, and 0.3 mg/ml) of [
3H]-cholesteryl
oleolyl ether labeled hHDL3 for 3 hrs. Selective cholesterol uptake
showed an almost linear response to hHDL3 loading and was
similar for cells from WT and CD36
2/2 mice as shown in
Figure 2C.
Cholesteryl ester in HDL can be transferred to apoB-containing
lipoproteins and taken up by the liver via the LDL receptor[33].
The possibility that this pathway is enhanced in CD36
2/2
hepatocytes was tested using
3H-cholesterol oleate labeled hLDL
and as shown in Figure 2D, no genotype related difference was
observed. The above data indicated that hepatocyte handling of
CE from HDL or LDL was unaltered by CD36 deficiency.
Efflux of cholesterol and phospholipids from primary
hepatocytes
The possibility that there was alteration of cholesterol efflux by
the CD36
2/2 liver was tested next. Cholesterol efflux from
hepatocytes can influence plasma HDL concentrations. In
addition efflux of cholesterol especially that mediated by the
ABCA1 transporter is coupled to that of phospholipids[6]. As
shown earlier in Table 1, differences in both plasma cholesterol
and phospholipid levels were measured in CD36
2/2 as compared
to WT mice. We examined efflux efficiency of these lipids by
primary hepatocytes isolated from both mice groups. Freshly
isolated hepatocytes were first loaded with
14C-cholesterol or with
3H-choline chloride (to label cell phospholipids). Cells were then
allowed to efflux
14C-cholesterol or
3H-phosphotidylcholine to
HDL3 0.1 mg/ml overnight. Surprisingly, as shown in Figure 3A
and B, CD36
2/2 hepatocytes had significantly higher cholesterol
and phospholipid efflux efficiency. At the end of the incubation
with HDL3, about 30% of labeled cholesterol effluxed into the
medium in WT hepatocytes as compared to 50% for CD36
2/2
cells (Fig. 3A). CD36
2/2 cells also effluxed a higher proportion of
Figure 1. Effect of a cholesterol rich diet on plasma cholesterol and apolipoprotein content of HDL subfractions in WT and CD36
null (CD36
2/2) mice. Pooled plasma (4–5 mice per genotype) collected in the postprandial state (5–6 hrs after food removal) was used for
fractionation. Panels A and B: Cholesterol content of FPLC fractions, WT (solid line), CD36
2/2 (dashed line), female (A), male (B). Panel C: Western
blot of plasma apolipoproteins from mice fed CHOW or high fat high cholesterol (HFHC). Panels D and E: Expanded graphs showing cholesterol in
HDL subfractions 26–42 and the corresponding apolipoprotein distribution. HDL fractions were separated by SDS-PAGE and blotted against
polyclonal antibodies for apoA-I and apoA-IV. Data are representative of two fractionation assays per experiment from two separate experiments.
doi:10.1371/journal.pone.0009906.g001
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CD36 may negatively influence hepatic cholesterol and phospho-
lipid efflux so this is enhanced in CD36 deficiency.
Cholesterol and phospholipid efflux from hepatocytes is
primarily facilitated by the ATP cassette transporters ABCA1
and ABCG1[34] with a more minor role for SR-B1[35]. We
examined whether increased cholesterol efflux was due to
increases in these proteins. However, Western analysis using liver
homogenates showed no differences between genotypes (Fig. 3C).
Synthesis and secretion of ApoA-I and IV by isolated
hepatocytes
Elevated HDL can result from over-production of apoA-I[36].
In addition as shown in Figure 1, CD36
2/2 mice had higher
plasma levels of HDL apolipoproteins, so we examined whether
CD36 deficiency alters hepatic apoA-I and apoA-IV production
and secretion. Hepatocytes from WT and CD36
2/2 mice were
labeled with
35S for 3 hr then cellular and medium apoA-I and
apoA-IV were immunoprecipitated using the respective antibod-
ies. Figure 3D shows that apoA-I and apoA-IV synthesis and
secretion were increased in CD36
2/2 as compared to WT cells
(p=0.011 and 0.002 for cellular and media apoA-I content
respectively). This suggested that enhanced production of HDL
apolipoproteins may contribute to the high HDL in CD36
2/2
mice.
To determine whether the increased synthesis of apoA-I and
apoA-IV in CD36
2/2 hepatocytes involved transcriptional or
post-translational mechanisms, we measured hepatic mRNA of
the corresponding genes. Levels of APOA-I and APOA-IV mRNA
were significantly higher in CD36
2/2 livers (Fig. 3E). Hepatic
expression of apoA-I and apoA-IV is regulated by many factors,
including pregnane X receptor (PXR) and hepatocyte nuclear
factor 4 (HNF4)[37]. RT-PCR showed that PXR expression in
CD36
2/2 liver was significantly increased while that of HFN4
and LXR was unaltered (Fig. 3F). PXR represses transcription of
genes involved in lipid b-oxidation, such as carnitine palmitoyl
transferase 1(CPT1) and 3-Hydroxy-3-Methylglutaryl CoA Re-
ductase (HMGCR)[38]. Consistent with enhanced PXR expression,
hepatic CPT1b and HMGCR expression was significantly lower
in CD36
2/2 as compared to WT mice (Fig. 3E). Expression of
ABCA1 was slightly increased while that of ABCG1 was not
altered.
Figure 2. HDL clearance in vivo and cholesterol uptake by isolated hepatocytes in vitro. Panels A and B: In vivo HDL clearance. 200 mlo f
[
3H]- and [
125I]-dual labeled human HDL was injected into the mouse tail vein and plasma radioactivity (panel A: [
3H] and panel B: [
125I]) was
measured at the times indicated. Five females and 10 males were used per genotype. Panels C and D: In vitro cholesterol uptake. Hepatocytes
isolated from WT and CD36
2/2 mice, were plated at a density of 0.5610
6 cells/well and assayed for cholesterol uptake, using either HDL or LDL.
Panel C: Cholesterol uptake from HDL using three concentrations of
3H-cholesteryl oleolyl ether labeled human HDL3 for 3 hours. Panel D:
Cholesterol uptake from LDL with cells incubated with
3H-cholesteryl oleolyl labeled native hLDL for 5 hr. Data are means (n=4) shown with standard
errors and representative of two separate experiments.
doi:10.1371/journal.pone.0009906.g002
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2/2 mice have
increased hepatic apoA-I and apoA-IV synthesis and secretion
as well as enhanced hepatocyte cholesterol and phospholipid
efflux. Both changes would contribute to elevating plasma HDL in
CD36 deficiency.
Efflux of cholesterol and phospholipids from isolated
macrophages
A cell type that is central to cholesterol homeostasis is the
macrophage. Conversion of macrophages to lipid laden foam cells
as a result of excess cholesterol uptake or defective cholesterol
efflux is implicated in lesion development[6]. CD36 deficiency
reduces uptake of modified lipoproteins by macrophages limiting
foam cell formation[2]. We examined whether the deficiency
also influences macrophage cholesterol efflux similar to its effect
on hepatocytes. Intraperitoneal macrophages from WT and
CD36
2/2 mice were assayed for capacity to efflux CE to HDL.
In a first approach, macrophages were preloaded overnight with
[
3H]-cholesterol oleate labeled ac-LDL (1.0610
6 dpm/mg pro-
tein). The washed cells were switched to serum-free RPMI
containing 0.1 mg/ml hHDL2 for 12 hrs and then cells and media
were collected for [
3H] counts.
CD36
2/2 macrophages demonstrated the expected impairment
of ac-LDL cholesterol uptake[5] accumulating about 25% of
counts recovered in WT cells (Fig. 4A). However, despite the lower
level of cholesterol loaded into CD36
2/2 cells, a similar amount of
[
3H]-cholesterol effluxed into the HDL containing medium
(Fig. 4B). Percent cholesterol efflux ([
3H] in media/total [
3H]
adjusted by protein content) for CD36
2/2 macrophages was
about 4–6% as compared to ,1% for WT cells (Fig. 4C). To
separate cholesterol uptake and efflux we equalized cellular
cholesterol loading before efflux initiation by incubating macro-
phages with unmodified LDL labeled with [
14C]-cholesterol. LDL
uptake by macrophage is mediated by the LDL receptor[5,39]
independent of CD36 so [
14C]-LDL loading resulted in similar
[
14C]-cholesterol accumulation by WT and CD36
2/2 macro-
phages (p=0.37, Fig. 4D). Again, as shown in Figure 4E, cells
from CD36
2/2 mice effluxed more [
14C]-cholesterol into the
medium (p=0.042), and had significantly higher efflux efficiency
(p=0.049, Fig. 4F). Thus the enhanced cholesterol efflux of
CD36
2/2 cells was independent of cellular cholesterol.
Some studies suggested that cholesterol efflux mediated by
ABCA1 favors lipid-poor apoA-I instead of HDL particles[6]. We
also conducted efflux experiments using 50 mg/ml human apoA-I
as the lipid acceptor. As shown in Figure 4G–H, cells from
CD36
2/2 mice effluxed more cholesterol to media apoA-I
(p=0.003, Figure 4H) and had higher efflux efficiency than WT
cells (p=0.047, Figure 4I).
To examine PL efflux, macrophages were preincubated with
[
3H]-choline (24 hrs), washed and switched to medium containing
0.2 mg/ml human HDL2 for 8 hrs. Radioactivity was determined
in lipid extracts of cells and medium. Figure 5A shows that [
3H]
incorporation into cellular PL was similar for WT and CD36
2/2
macrophages. However, as with cholesterol, CD36
2/2 macro-
phages showed enhanced PL efflux (Fig. 5B), and efflux efficiency
(Fig. 5C).
Cholesterol and phospholipid efflux from macrophage is
primarily facilitated by ABCA1 and to a lesser extent by
ABCG1[34] and SR-B1[35]. ABCA1 expression in macrophages
is stimulated by liver-X-receptors (LXRs) which in turn is
modulated by peroxisome proliferator-activated receptor gamma
(PPARc)[30]. We examined whether CD36 deficiency associates
with alterations in protein levels of PPARc, ABCA1, ABCG1 and
SR-B1. As Figure 6A shows, there were no noticeable differences
in the amount of these proteins between WT and CD36
2/2
macrophages. ABCA1 recycles between plasma membrane and
intracellular compartments and membrane transporter content
can be altered without changes in total ABCA1 protein[40]. We
determined whether CD36 deficiency alters ABCA1 membrane
content by biotin labeling of macrophage surface proteins. As
shown in Figure 6B, these assays documented a significant
increase of cell surface ABCA1 in CD36
2/2 as compared to
WT macrophages. In contrast, cell-surface SR-B1 was minimally
altered. When cell surface ABCA1 was adjusted by cell mem-
brane marker Cadherin 1 (CDH1), membrane-bound ABCA1 in
CD36
2/2 cells was almost double that in WT cells (p=0.03,
Figure 6C). These data suggested that CD36 increases cholesterol
efflux in macrophages at least in part by influencing cell
membrane ABCA1 distribution. A similar increase in surface
ABCA1 was observed in CD36
2/2 hepatocytes suggesting that
this interpretation may also apply to cholesterol efflux from these
cells (Figure S1). Although preparations of isolated hepatocytes are
largely pure as a result of the fact that hepatocytes are the major
cell type in the liver, he possibility that the increase in cholesterol
efflux from hepatocytes could reflect contaminating macrophages
was ruled out by assaying expression of the macrophage specific
marker F4/80. As shown in Figure S2, F4/80 levels in the
hepatocyte preparations were very low to undetectable.
Discussion
There is strong evidence in rodent models and humans to
support a role of CD36 in uptake of FA and oxidized lipoproteins
and in mediating signal transduction in response to these
ligands[1,2]. CD36 is also a high affinity receptor for native
lipoproteins as reported in 1998[8]. However, its role in the
metabolism of these particles has been relatively little studied.
Recent work documented that CD36 can facilitate CE uptake
from native LDL and that it delays LDL clearance in vivo[5]. In the
case of HDL, CD36 binds these particles as well as SR-B1 but is
less efficient in mediating selective HDL-CE uptake and does not
promote whole particle endocytosis[9,10,41,42,43]. In vivo CD36
overexpression in the liver did not alter plasma HDL in mice so
Figure 3. Hepatocytes from WT and CD36
2/2 mice. Cholesterol and phospholipid efflux, apoA-I production and expression of genes that
regulate cholesterol metabolism. Primary hepatocytes were isolated from WT and CD36
2/2 mice and assayed for cholesterol and phospholipid efflux.
Hepatocytes were loaded with
14C-cholesterol and
3H-choline chloride (to label cell phospholipids) as described in Methods. Cells were then allowed
to efflux
14C-cholesterol and
3H-phosphotidylcholine overnight. Panel A: cholesterol efflux and Panel B: phospholipid efflux for WT and CD36
2/2
hepatocytes. Data (DPM adjusted for cellular protein) are means (n=4) shown with standard errors and typical of three experiments. Panel C:
Western blot showing expression of proteins related to cholesterol and phospholipid efflux. Data are representative of three separate experiments.
Panel D: ApoA-I production and secretion assayed in primary hepatocytes labeled with
35S. Data are from two separate experiments with 3
independent samples in each experiment. Relative band intensity (intensity of apoA-I/intensity of albumin band) was quantified using ImageJ
software (http://rsbweb.nih.gov/ij/). ApoA-I levels were significantly higher in CD36
2/2 as compared to WT hepatocytes (p=0.011 and 0.002 for cell
and media respectively). ApoA-IV secretion was significantly higher in CD36
2/2 (p=0.008), but not production (p.0.05). Panel E: Gene expression
measured by RT-PCR of transcriptional factors that regulate apoA-I expression and Panel F: of genes targeted by PXR. In both panel E and F, n=6 on
each assay plate, and data are representative of three separate experiments.
doi:10.1371/journal.pone.0009906.g003
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considered minimal[10]. Our recent family based association
study in a large African American population sample, identified a
surprising number of CD36 SNPs that influenced plasma
HDL[17]. These findings, together with the earlier observation
of high cholesterol and HDL levels in CD36 knockout mice[11]
led us to consider a potential physiological role of CD36 in HDL
metabolism, which was explored in the present study. HDL
Figure 4. Cholesterol efflux in macrophages from WT and CD362/2 mice using different lipoprotein substrates. Macrophages isolated
from WT and CD36
2/2 mice were cholesterol loaded by preincubation (12 hr) with
3H-cholesterol oleate labeled ac-LDL (panels A, B and C)o r
14C-
cholesterol labeled native LDL (panels D, E, F, G, H, and I). For cholesterol efflux assays, the cells were switched to a serum-free medium containing
0.1 mg/ml human HDL2- for 8 hours. Media and cells were then collected and assayed for radioactivity. Panel A: Cholesterol uptake from ac-LDL by
CD36
+/+ and CD36
2/2 macrophages. Panel B: Cholesterol efflux into HDL-containing medium. Panel C: Efflux efficiency,
3H-cholesterol oleate efflux
expressed as percent of cellular
3H at efflux initiation. Data are means (n=4) shown with standard errors and are typical of three separate
experiments. Panel D to F: macrophage efflux assay using hHDL2 as efflux substrate. Panel D: [
14C]-cholesterol uptake by macrophages preincubated
with native
14C-LDL (0.3 mg/ml). Panel E: Cholesterol efflux by 50 mg/ml HDL2 (DPM adjusted for cell protein). Panel F: Efflux efficiency (percent of
total
14C in the media adjusted by protein content). Data are means with standard errors (n=4) typical of three separate experiments. Panel G to I:
macrophage efflux assay using human apoA-I as efflux substrate. Panel G: [
14C]-cholesterol uptake by macrophages preincubated with native
14C-
LDL (0.3 mg/ml). Panel H: Cholesterol efflux by 50 mg/ml human apoA-I (DPM adjusted for cell protein). Panel I: Efflux efficiency (percent of total
14C counts in the media adjusted by protein content). Data are means with standard errors (n=4).
doi:10.1371/journal.pone.0009906.g004
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2/2 mice and impact of CD36
deficiency on cholesterol uptake and efflux in primary hepatocytes
and macrophages were examined. The findings document that
CD36 influences plasma apoA-I, apoA-IV, cholesterol and
phospholipid levels. The mechanisms involved include increased
hepatic expression and synthesis of HDL apolipoproteins and
enhanced efflux of cholesterol and phospholipids by hepatocytes
and macrophages. The data demonstrate a novel role of CD36 in
the regulation of reverse cholesterol transport.
CD36 null mice, regardless of sex, exhibited an exaggerated
response of plasma HDL to increased dietary supply of cholesterol.
HDL levels were substantially higher in CD36
2/2 mice and
parallel increases were measured in plasma phospholipids and
cholesterol. HDL clearance in mice is mainly accomplished via
selective CE uptake by the liver primarily via SR-B1 (reviewed in
[7,44]). Reduced activity of hepatic SR-B1 impedes HDL
clearance and increases serum HDL levels [45,46,47]. CD36
expression in the liver is relatively low but levels are up-regulated
under various conditions associated with steatosis[5,48]. The low
hepatic CD36 levels, the previous demonstration that CD36 is less
efficient than SR-B1 in selective HDL-CE uptake, and the finding
that hepatic CD36 overexpression in mice did not alter plasma
HDL levels[10] suggested that CD36 function in HDL clearance
may not be relevant physiologically[9,10]. Our findings using the
opposite condition of CD36 deletion also demonstrate that in vivo
the protein does not significantly contribute to HDL clearance.
Absence of CD36 did not alter kinetics of labeled HDL in vivo and
CD36 deficient hepatocytes assayed in vitro exhibited rates of HDL
uptake that were similar to CD36 sufficient hepatocytes. Thus
defective HDL clearance is not responsible for the elevated HDL
in CD36
2/2 mice or for the exaggerated response of plasma
cholesterol and phospholipids in these mice to the high cholesterol
diet.
The mechanisms underlying the effect of CD36 deficiency
on HDL levels involve a combination of increased hepatic
apoA production and enhanced cellular efflux of cholesterol
and phospholipids. ApoA-I is the major HDL apolipoprotein and
is mainly synthesized in the liver[37]. ApoA-I regulation is
transcriptional[37] or post-transcriptional[49]. ApoA-I expression
Figure 5. Phospholipid efflux in macrophages from WT and
CD362/2 mice. Panel A: Content of
3H-labeled phospholipids in
macrophages preincubated with 0.5 mCi/ml of [
3H]-choline chloride for
24 hours. Panel B: PL efflux (DPM/cell protein) into serum-free RPMI with
hHDL2 for 8 hr. Panel C: Efflux efficiency. Data are means (n=4) shown
with standard errors and are typical of three separate experiments.
doi:10.1371/journal.pone.0009906.g005
Figure 6. Total and cell surface proteins in primary macrophages from WT and CD36
2/2 mice. Panel A. Total protein content,
determined by western blot for macrophages isolated and pooled from 4–5 mice per genotype. Detection was by infrared secondary antibodies.
Panel B: Cell-surface proteins determined using biotin labeling as described in Methods (first row). CDH1 was used as a cell surface protein marker
(the second row). Total cellular ABCA1 for respective samples was listed in the third row. Panel C. Relative intensities of the macrophages surface
proteins ABCA1 between WT and CD36
2/2 mice. Intensity of protein bands (ABCA1) from 8 independent samples (4 WT and 4 CD36
2/2) were
quantified and expressed as a relative intensity of intensity of CDH1 in the same sample.
doi:10.1371/journal.pone.0009906.g006
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synthesis in livers of CD36
2/2 deficient mice may reflect a PXR-
mediated increase in apoA-I gene transcription. Like apoA-I,
CD36 is a direct target of PXR[48] and the increased PXR
expression in the CD36
2/2 liver suggests a regulatory loop similar
to the one that exists between CD36 and PPARd[31].
The enhanced apoA supply in CD36
2/2 mice would promote
reverse cholesterol transport in vivo but it does not explain the
enhanced efflux of cholesterol that is observed in isolated CD36
2/2
hepatocytes and macrophages in vitro. The elevated cholesterol/PL
efflux in CD36
2/2 cells appears dueat least in part to enhanced cell
surface ABCA1 re-distribution. ABCA1 is present in the plasma
membrane as well as in subcellular compartments such as late
endosomes and lysosomes[50]. Internalization and recycling of
ABCA1 are integral to cholesterol mobilization, which involves
cholesterol pools in the membrane, the endoplasmic reticulum in
addition to endocytic and lysosomal compartments[28,50]. CD36
may influence ABCA1 recycling directly or via altering distribution
of cholesterol and phospholipids in intracellular pools related
to apoA-I or nascent HDL lipidation. Recent evidence points
to the important role of lipid droplets in distributing various lipids
to membrane-bound intracellular organelles[51,52,53]. CD36 is
among proteins identified on lipid droplets by proteomic studies
[[54] and N Wolins, personal communication] but whether it plays
a role in droplet formation is unknown. In human carotid lesion
samples, CD36 expression positively correlates with adipophilin
(ADRP)[55], a lipid droplet protein that also influences cellular
cholesterol distribution[56] and efflux[57]. ADRP protein levels are
significantly reduced in CD36
2/2 macrophages (Fig. S3). Thus
CD36 may impact ABCA1 localization and cholesterol efflux via
influencing intracellular lipid partitioning, which would be
consistent with its effect on lipoprotein production in the
intestine[14] and possibly the liver (Fig. 3). ABCA1 trafficking
involves rab proteins[40] and the possibility that these may be
altered in CD36
2/2 cells will also need to be considered.
Overall the findings both in vivo and in primary cells in vitro
support a negative relationship between CD36 expression and
HDL formation. They provide potential mechanisms for the
associations observed in humans between polymorphisms in the
CD36 gene and plasma HDL[17]. A coding variant that results in
partial CD36 protein deficiency associated with higher HDL levels
and was protective against the metabolic syndrome. Furthermore,
our unpublished findings in humans [Love-Gregory et al] indicate
that monocyte CD36 level is inversely related to plasma HDL.
Thus it is possible that an important influence of CD36 in vivo is on
cholesterol efflux and reverse cholesterol transport. CD36
downregulation may be beneficial for protection from atheroscle-
rotic disease as it would reduce foam cell formation via enhancing
cholesterol efflux in addition to reducing cholesterol uptake by
macrophages.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0009906.s001 (0.04 MB
DOC)
Figure S1
Found at: doi:10.1371/journal.pone.0009906.s002 (0.05 MB
DOC)
Figure S2
Found at: doi:10.1371/journal.pone.0009906.s003 (0.03 MB
DOC)
Figure S3
Found at: doi:10.1371/journal.pone.0009906.s004 (0.10 MB
DOC)
Acknowledgments
The authors thank Dr. Trey Coleman for technical advice with HDL
fractionation.
Author Contributions
Conceived and designed the experiments: PY ZC CBM BNF NA.
Performed the experiments: PY ZC FN. Analyzed the data: PY.
Contributed reagents/materials/analysis tools: PY CBM BNF SA. Wrote
the paper: PY NA.
References
1. Su X, Abumrad NA (2009) Cellular fatty acid uptake: a pathway under
construction. Trends Endocrinol Metab 20: 72–77.
2. Silverstein RL, Febbraio M (2009) CD36, a scavenger receptor involved in
immunity, metabolism, angiogenesis, and behavior. Sci Signal 2: re3.
3. Nicholson AC, Febbraio M, Han J, Silverstein RL, Hajjar DP (2000) CD36
in atherosclerosis. The role of a class B macrophage scavenger receptor.
Ann N Y Acad Sci 902: 128–131; discussion 131-123.
4. Zeng Y, Tao N, Chung KN, Heuser JE, Lublin DM (2003) Endocytosis of
oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid
raft pathway that does not require caveolin-1. J Biol Chem 278: 45931–45936.
5. Luangrath V, Brodeur MR, Rhainds D, Brissette L (2008) Mouse CD36 has
opposite effects on LDL and oxidized LDL metabolism in vivo. Arterioscler
Thromb Vasc Biol 28: 1290–1295.
6. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N (2008) HDL, ABC
transporters, and cholesterol efflux: implications for the treatment of
atherosclerosis. Cell Metab 7: 365–375.
7. Zannis VI, Chroni A, Krieger M (2006) Role of apoA-I, ABCA1, LCAT, and
SR-BI in the biogenesis of HDL. J Mol Med 84: 276–294.
8. Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA (1998)
Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL,
and VLDL. J Lipid Res 39: 777–788.
9. Connelly MA, Klein SM, Azhar S, Abumrad NA, Williams DL (1999)
Comparison of class B scavenger receptors, CD36 and scavenger receptor BI
(SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl
ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl
ester uptake. J Biol Chem 274: 41–47.
10. de Villiers WJ, Cai L, Webb NR, de Beer MC, van der Westhuyzen DR, et al.
(2001) CD36 does not play a direct role in HDL or LDL metabolism. J Lipid Res
42: 1231–1238.
11. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, et al. (1999) A null
mutation in murine CD36 reveals an important role in fatty acid and lipoprotein
metabolism. J Biol Chem 274: 19055–19062.
12. Chahil TJ, Ginsberg HN (2006) Diabetic Dyslipidemia. Endocrinology &
Metabolism Clinics of North America 35: 491–510.
13. Weinstock PH, Bisgaier CL, Aalto-Setala K, Radner H, Ramakrishnan R, et al.
(1995) Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal
death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired
very low density lipoprotein clearance in heterozygotes. J Clin Invest 96: 2555–2568.
14. Drover VA, Ajmal M, Nassir F, Davidson NO, Nauli AM, et al. (2005) CD36
deficiency impairs intestinal lipid secretion and clearance of chylomicrons from
the blood. J Clin Invest 115: 1290–1297.
15. Goudriaan JR, den Boer MA, Rensen PC, Febbraio M, Kuipers F, et al. (2005)
CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride
clearance. J Lipid Res 46: 2175–2181.
16. An P, Freedman BI, Hanis CL, Chen Y-DI, Weder AB, et al. (2005) Genome-
wide Linkage Scans for Fasting Glucose, Insulin, and Insulin Resistance in the
National Heart, Lung, and Blood Institute Family Blood Pressure Program.
Diabetes 54: 909–914.
17. Love-Gregory L, Sherva R, Sun L, Wasson J, Schappe T, et al. (2008) Variants
in the CD36 gene associate with the metabolic syndrome and high-density
lipoprotein cholesterol. Hum Mol Genet 17: 1695–1704.
18. Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical
composition of ultracentrifugally separated lipoproteins in human serum. J Clin
Invest 34: 1345–1353.
19. Basu SK, Goldstein JL, Anderson GW, Brown MS (1976) Degradation of
cationized low density lipoprotein and regulation of cholesterol metabolism in
homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A
73: 3178–3182.
CD36 Influences HDL Metabolism
PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e990620. Feng B, Tabas I (2002) ABCA1-mediated cholesterol efflux is defective in free
cholesterol-loaded macrophages. Mechanism involves enhanced ABCA1
degradation in a process requiring full NPC1 activity. J Biol Chem 277:
43271–43280.
21. Azhar S, Tsai L, Reaven E (1990) Uptake and utilization of lipoprotein
cholesteryl esters by rat granulosa cells. Biochim Biophys Acta 1047: 148–160.
22. Zhang JR, Coleman T, Langmade SJ, Scherrer DE, Lane L, et al. (2008)
Niemann-Pick C1 protects against atherosclerosis in mice via regulation of
macrophage intracellular cholesterol trafficking. J Clin Invest 118: 2281–2290.
23. Jones C, Garuti R, Michaely P, Li WP, Maeda N, et al. (2007) Disruption of
LDL but not VLDL clearance in autosomal recessive hypercholesterolemia.
J Clin Invest 117: 165–174.
24. Chen Z, Fitzgerald RL, Averna MR, Schonfeld G (2000) A targeted
apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to
the reduced ability of apolipoprotein B-38.9 to transport triglycerides. J Biol
Chem 275: 32807–32815.
25. Mehrdad H, James BM (1995) 9-cis-retinoic acid increases apolipoprotein AI
secretion and mRNA expression in HepG2 cells. Atherosclerosis 117: 199–207.
26. Park YM, Febbraio M, Silverstein RL (2009) CD36 modulates migration of
mouse and human macrophages in response to oxidized LDL and may
contribute to macrophage trapping in the arterial intima. J Clin Invest 119:
136–145.
27. Waddington EI, Boadu E, Francis GA (2005) Cholesterol and phospholipid
efflux from cultured cells. Methods 36: 196–206.
28. Hassan HH, Bailey D, Lee D-YD, Iatan I, Hafiane A, et al. (2008) Quantitative
Analysis of ABCA1-dependent Compartmentalization and Trafficking of
Apolipoprotein A-I. Journal of Biological Chemistry 283: 11164–11175.
29. Drover VA, Nguyen DV, Bastie CC, Darlington YF, Abumrad NA, et al. (2008)
CD36 mediates both cellular uptake of very long chain fatty acids and their
intestinal absorption in mice. J Biol Chem 283: 13108–13115.
30. Tall AR (2008) Cholesterol efflux pathways and other potential mechanisms
involved in the athero-protective effect of high density lipoproteins. J Intern Med
263: 256–273.
31. Nahle Z, Hsieh M, Pietka T, Coburn CT, Grimaldi PA, et al. (2008) CD36-
dependent regulation of muscle FoxO1 and PDK4 in the PPAR delta/beta-
mediated adaptation to metabolic stress. J Biol Chem 283: 14317–14326.
32. Kersten S (2008) Peroxisome proliferator activated receptors and lipoprotein
metabolism. PPAR Res 132960 2008: 132960.
33. Rader DJ (2003) Regulation of reverse cholesterol transport and clinical
implications. Am J Cardiol 92: 42J–49J.
34. Oram JF, Vaughan AM (2006) ATP-Binding cassette cholesterol transporters
and cardiovascular disease. Circ Res 99: 1031–1043.
35. Chroni A, Nieland TJ, Kypreos KE, Krieger M, Zannis VI (2005) SR-BI
mediates cholesterol efflux via its interactions with lipid-bound ApoE. Structural
mutations in SR-BI diminish cholesterol efflux. Biochemistry 44: 13132–13143.
36. Srivastava RA (2000) Apolipoprotein E gene expression is reduced in
apolipoprotein A-I transgenic mice. Mol Cell Biochem 209: 125–129.
37. Malik S (2003) Transcriptional regulation of the apolipoprotein AI gene. Front
Biosci 8: d360–368.
38. Wada T, Gao J, Xie W (2009) PXR and CAR in energy metabolism. Trends
Endocrinol Metab 20: 273–279.
39. Johnson LA, Altenburg MK, Walzem RL, Scanga LT, Maeda N (2008) Absence
of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100
without the putative receptor-binding sequences. Arterioscler Thromb Vasc Biol
28: 1745–1752.
40. Linder MD, Mayranpaa MI, Peranen J, Pietila TE, Pietiainen VM, et al. (2009)
Rab8 regulates ABCA1 cell surface expression and facilitates cholesterol efflux in
primary human macrophages. Arterioscler Thromb Vasc Biol 29: 883–888.
41. Sun B, Boyanovsky BB, Connelly MA, Shridas P, van der Westhuyzen DR, et al.
(2007) Distinct mechanisms for OxLDL uptake and cellular trafficking by class B
scavenger receptors CD36 and SR-BI. J Lipid Res 48: 2560–2570.
42. Gu X, Kozarsky K, Krieger M (2000) Scavenger receptor class B, type I-
mediated [3H]cholesterol efflux to high and low density lipoproteins is
dependent on lipoprotein binding to the receptor. J Biol Chem 275:
29993–30001.
43. Gu X, Trigatti B, Xu S, Acton S, Babitt J, et al. (1998) The efficient cellular
uptake of high density lipoprotein lipids via scavenger receptor class B type I
requires not only receptor-mediated surface binding but also receptor-specific
lipid transfer mediated by its extracellular domain. J Biol Chem 273:
26338–26348.
44. Connelly MA, Williams DL (2004) Scavenger receptor BI: a scavenger receptor
with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol 15:
287–295.
45. Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, et al. (1999) Hepatic
scavenger receptor BI promotes rapid clearance of high density lipoprotein free
cholesterol and its transport into bile. J Biol Chem 274: 33398–33402.
46. Ueda Y, Royer L, Gong E, Zhang J, Cooper PN, et al. (1999) Lower plasma
levels and accelerated clearance of high density lipoprotein (HDL) and non-
HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol
Chem 274: 7165–7171.
47. Arai T, Rinninger F, Varban L, Fairchild-Huntress V, Liang CP, et al. (1999)
Decreased selective uptake of high density lipoprotein cholesteryl esters in
apolipoprotein E knock-out mice. Proc Natl Acad Sci U S A 96: 12050–12055.
48. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, et al. (2008) Hepatic fatty acid
transporter Cd36 is a common target of LXR, PXR, and PPARgamma in
promoting steatosis. Gastroenterology 134: 556–567.
49. Sviridov D (2009) Maturation of apolipoprotein A-I: unrecognized health benefit
or a forgotten rudiment? J Lipid Res 50: 1257–1258.
50. Neufeld EB, Stonik JA, Demosky SJ, Jr., Knapper CL, Combs CA, et al. (2004)
The ABCA1 transporter modulates late endocytic trafficking: insights from the
correction of the genetic defect in Tangier disease. J Biol Chem 279:
15571–15578.
51. Liu P, Bartz R, Zehmer JK, Ying Y, Anderson RG (2008) Rab-regulated
membrane traffic between adiposomes and multiple endomembrane systems.
Methods Enzymol 439: 327–337.
52. Zehmer JK, Huang Y, Peng G, Pu J, Anderson RG, et al. (2009) A role for lipid
droplets in inter-membrane lipid traffic. Proteomics 9: 914–921.
53. Ducharme NA, Bickel PE (2008) Lipid droplets in lipogenesis and lipolysis.
Endocrinology 149: 942–949.
54. Brasaemle DL, Dolios G, Shapiro L, Wang R (2004) Proteomic analysis of
proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-
L1 adipocytes. J Biol Chem 279: 46835–46842.
55. Collot-Teixeira S, Barbatis C, Bultelle F, Koutouzis M, Pasterkamp G, et al.
(2008) CD36 is significantly correlated with adipophilin in human carotid lesions
and inversely correlated with plasma ApoAI. J Biomed Biotechnol 2008:
813236.
56. Buers I, Robenek H, Lorkowski S, Nitschke Y, Severs NJ, et al. (2009) TIP47, a
Lipid Cargo Protein Involved in Macrophage Triglyceride Metabolism.
Arterioscler Thromb Vasc Biol.
57. Larigauderie G, Furman C, Jaye M, Lasselin C, Copin C, et al. (2004)
Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1
macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol 24:
504–510.
CD36 Influences HDL Metabolism
PLoS ONE | www.plosone.org 11 March 2010 | Volume 5 | Issue 3 | e9906